PUBLISHER: Grand View Research | PRODUCT CODE: 1869706
PUBLISHER: Grand View Research | PRODUCT CODE: 1869706
The global precision medicine software market size was valued at USD 2.12 billion in 2024 and is projected to reach USD 5.66 billion by 2033, growing at a CAGR of 11.8% from 2025 to 2033. This growth is attributed to declining cost of genome sequencing, rise of targeted and personalized therapies, the increase of decentralized trials, and real-world evidence.
Moreover, government and institutional initiatives supporting genomics and precision medicine, and demand for personalized healthcare, have fueled the industry outlook. The declining cost of genome sequencing has transformed it from a high-cost, research-only tool into a routine part of clinical practice, making it a key driver of the precision medicine software industry. What once cost nearly USD 100 million per genome in the early 2000s can now be performed for under USD 500, enabling widespread adoption by hospitals, diagnostic labs, pharmaceutical companies, and even consumer health firms.
This affordability has led to a surge in large-scale genomic testing, generating massive datasets that require advanced software for storage, integration, and interpretation. Precision medicine software plays a central role in converting this raw sequencing data into actionable clinical insights for diagnosis, therapy selection, and patient stratification, driving demand as sequencing becomes standard in oncology, rare disease treatment, and preventive healthcare.
Global Precision Medicine Software Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global precision medicine software market report based on component, deployment mode, application, technology, therapeutic area, end use and region.